Can a new tracer light up tumors better than standard PET scans?

NCT ID NCT07741006

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants will receive a single injection of the new tracer and undergo additional PET imaging to evaluate its safety, how it spreads through the body, and whether it can detect tumors as well as or better than the standard scan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[68Ga]Ga-ELI411, an experimental PET imaging tracer
What this could lead to
If successful, this could lead to a more precise PET imaging method for detecting and evaluating solid tumors, potentially improving cancer diagnosis and treatment planning.
What could go wrong
This is an early-phase, small study (18 participants) focused on safety and imaging performance, not treatment. The tracer may not prove more effective than existing FDG-PET, and results may not generalize beyond the specific patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Union Hospital, Huazhong University of Science and Technology

    Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.